Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR A peek behind the scenes: Just how are our funding decisions... July 6, 2022 EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected... February 2, 2026 Load more HOT NEWS Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... A urine test for bladder cancer: What’s the latest? Trial Suggests Expanded Role for Blinatumomab in Treating ALL Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting...
